Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1293377.RAZ6AnQDF_r-e6c35BFywXnXbW_qhikB_Ld4hprHeZEuI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1293377.RAZ6AnQDF_r-e6c35BFywXnXbW_qhikB_Ld4hprHeZEuI130_assertion type Assertion NP1293377.RAZ6AnQDF_r-e6c35BFywXnXbW_qhikB_Ld4hprHeZEuI130_head.
- NP1293377.RAZ6AnQDF_r-e6c35BFywXnXbW_qhikB_Ld4hprHeZEuI130_assertion description "[In melanoma patients treated with an immune checkpoint therapy, high viral defense signature expression in tumors significantly associates with durable clinical response and DNMTi treatment sensitizes to anti-CTLA4 therapy in a pre-clinical melanoma model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1293377.RAZ6AnQDF_r-e6c35BFywXnXbW_qhikB_Ld4hprHeZEuI130_provenance.
- NP1293377.RAZ6AnQDF_r-e6c35BFywXnXbW_qhikB_Ld4hprHeZEuI130_assertion evidence source_evidence_literature NP1293377.RAZ6AnQDF_r-e6c35BFywXnXbW_qhikB_Ld4hprHeZEuI130_provenance.
- NP1293377.RAZ6AnQDF_r-e6c35BFywXnXbW_qhikB_Ld4hprHeZEuI130_assertion SIO_000772 26317466 NP1293377.RAZ6AnQDF_r-e6c35BFywXnXbW_qhikB_Ld4hprHeZEuI130_provenance.
- NP1293377.RAZ6AnQDF_r-e6c35BFywXnXbW_qhikB_Ld4hprHeZEuI130_assertion wasDerivedFrom befree-2016 NP1293377.RAZ6AnQDF_r-e6c35BFywXnXbW_qhikB_Ld4hprHeZEuI130_provenance.
- NP1293377.RAZ6AnQDF_r-e6c35BFywXnXbW_qhikB_Ld4hprHeZEuI130_assertion wasGeneratedBy ECO_0000203 NP1293377.RAZ6AnQDF_r-e6c35BFywXnXbW_qhikB_Ld4hprHeZEuI130_provenance.